Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 73 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Receptor Blockade Clear all

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Ianalumab, Placebo, Corticosteroids; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Yuma, Arizona • Clovis, California • Fountain Valley, California + 16 more

Conditions: Myocardial Remodeling
Interventions: Eplerenone, Lactose Tablet; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bipolar Disorder
Interventions: Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Pancreatic Cancer
Interventions: Gemcitabine, Nab paclitaxel, Proglumide, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: PCOS, Polycystic Ovary Syndrome
Interventions: Micronized progesterone, Placebo, Flutamide, Estradiol patch; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Erectile Dysfunction
Interventions: Naltrexone HCL/ Yohimbine HCL; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions: FG-3019, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more

Conditions: Coronary Artery Disease, Endothelial Dysfunction
Interventions: darusentan 100 mg; Drug
Lead sponsor: K.Lance Gould; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions: Losartan; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Humax-CD4, Placebo; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 50
States / cities: Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more

Conditions: Heart Failure
Interventions: Terbutaline plus Metoprolol or carvedilol; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: exemestane, triptorelin pamoate, capecitabine, methotrexate, vinorelbine tartrate, paclitaxel, therapeutic conventional surgery, radiation therapy, laboratory biomarker analysis; Drug · Procedure · Radiation + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: Metoprolol, Nebivolol; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Durvalumab, SNDX-6352; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions: Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure With Preserved Ejection Fraction, Hypertension
Interventions: Amlodipine Besylate, Metoprolol Succinate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo, Methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 26
States / cities: Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 22 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 3,080 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 143
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more

Conditions: Urothelial Carcinoma
Interventions: Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more

Conditions: Adrenergic Beta-Receptor Blockader, Troponin Levels, Cardiomyopathy, Post-surgical
Interventions: metoprolol; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 51 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
Interventions: Motixafortide, Cemiplimab, Gemcitabine, Nab paclitaxel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more

Conditions: Melanoma Stage III, Melanoma Stage IV
Interventions: SX-682, Pembrolizumab; Drug · Biological
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 6
States / cities: Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions: DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions: Placebo, Ramipril, Valsartan; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Clozapine for Treatment-Resistant Mania

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

Effects of Yohimbine and Naltrexone on Sexual Function

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Darusentan Effect on PET Uptake Heterogeneity

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Beta-2 Polymorphisms and Beta Receptor Selectivity

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Pilot - Peri-operative Beta Blockade

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis